Related Experiment Video

Updated: Dec 17, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.8K

Long Non-Coding RNA-ATB Attenuates the Angiotensin II-Induced Injury of Vascular Endothelial Cell

Miao Wang1, Shouyi Gan1, Bin Li1

  • 1Deparment of Cardiovascular Medicine, Xian Ning Central Hospital, the First Affiliated Hospital of Hubei University of Science and Technology, Xian Ning Central Hospital, Xian'an District, Xian Ning City, Hubei Province, China.

Annals of Clinical and Laboratory Science
|June 26, 2020
PubMed
Abstract

Insights

Long noncoding RNA activated by transforming growth factor-II (lncRNA-ATB) plays a protective role in endothelial cell injury. Lower lncRNA-ATB levels correlate with cardiovascular disease development, impacting cell viability and apoptosis.

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • RNA Biology

Background:

  • Long noncoding RNA activated by transforming growth factor-II (lncRNA-ATB) is implicated in various cancers.
  • The role of lncRNA-ATB in cardiovascular disease and endothelial cell injury remains largely uncharacterized.

Purpose of the Study:

  • To investigate the expression and function of lncRNA-ATB in endothelial cell injury.
  • To elucidate the potential involvement of lncRNA-ATB in cardiovascular disease pathogenesis.

Main Methods:

  • Human umbilical vein endothelial cells (HUVECs) were subjected to Angiotensin II (Ang II)-induced injury.
  • lncRNA-ATB expression was quantified using qRT-PCR.
  • Cell viability and apoptosis were assessed via CCK-8 assay and flow cytometry.

Main Results:

  • Ang II treatment significantly downregulated lncRNA-ATB expression in HUVECs.
  • Knockdown of lncRNA-ATB exacerbated Ang II-induced endothelial cell injury, impairing viability and increasing apoptosis.
  • Overexpression of lncRNA-ATB demonstrated protective effects, inhibiting apoptosis and restoring cell viability.

Conclusions:

  • lncRNA-ATB expression is reduced during endothelial cell injury induced by Ang II.
  • lncRNA-ATB exhibits protective functions against endothelial cell injury.
  • These findings suggest lncRNA-ATB is a potential therapeutic target for cardiovascular disease.
Keywords:
Angiotensin IIcardiovascular diseasecell viabilityendothelial cellslncRNA-ATB

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.3K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
790
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.3K